Healthcare Industry News: metabolic disease
News Release - February 6, 2007
Tim Rothwell Appointed Chairman of Sanofi-aventis Group U.S. Pharmaceutical ActivitiesGreg Irace Named President and CEO of U.S. Pharmaceutical Operations
BRIDGEWATER, N.J., Feb. 6 (HSMN NewsFeed) -- Sanofi-aventis announced today that, effective February 1, Tim Rothwell has been appointed as Chairman of sanofi-aventis Group U.S. Pharmaceutical Activities in the United States, with direct responsibility for Communications and government policy. The company also announced that Greg Irace, who had been serving as Chief Financial Officer and Senior Vice President of Finance & Administration, has been appointed to succeed Tim as President and CEO of U.S. Pharmaceutical Operations.
The new appointments will allow Mr. Rothwell to focus broadly on Group operations in the U.S., including external sanofi-aventis efforts relating to Communications and government policy aimed at projecting and protecting the company's image and impact in the U.S. As President and CEO, Mr. Irace assumes executive leadership and management responsibility for the company's pharmaceutical business in the U.S.
No other corporate structural changes are planned at this time.
Sanofi-aventis is one of the world's leading pharmaceutical companies. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY ).
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.